282 related articles for article (PubMed ID: 23195005)
1. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
Hao WJ; Zong HT; Cui YS; Zhang Y
Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
3. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
Lü TM; Yang SL; Wu WZ; Tan JM
Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients.
Hill P; Cross NB; Barnett AN; Palmer SC; Webster AC
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD004759. PubMed ID: 28073178
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin.
Reddy KS; Devarapalli Y; Mazur M; Hamawi K; Chakkera H; Moss A; Mekeel K; Post D; Heilman R; Mulligan D
Transplant Proc; 2010; 42(6):2006-8. PubMed ID: 20692393
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis.
Shou ZF; Zhou Q; Cai JR; Cheng J; He Q; Wu JY; Chen JH
Chin Med J (Engl); 2009 Jul; 122(14):1692-8. PubMed ID: 19719973
[TBL] [Abstract][Full Text] [Related]
7. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
[TBL] [Abstract][Full Text] [Related]
8. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results.
Schulz T; Flecken M; Kapischke M; Busing M
Transplant Proc; 2005 May; 37(4):1818-20. PubMed ID: 15919476
[TBL] [Abstract][Full Text] [Related]
9. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
10. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years.
Stratta RJ; Alloway RR; Lo A; Hodge EE
Transplant Proc; 2005 Oct; 37(8):3531-4. PubMed ID: 16298651
[TBL] [Abstract][Full Text] [Related]
11. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
[TBL] [Abstract][Full Text] [Related]
12. Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation.
van den Hoogen MW; Hoitsma AJ; Hilbrands LB
Expert Opin Biol Ther; 2012 Aug; 12(8):1031-42. PubMed ID: 22583145
[TBL] [Abstract][Full Text] [Related]
13. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials.
Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J
Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365
[TBL] [Abstract][Full Text] [Related]
14. Pretransplantation GAD-autoantibody status to guide prophylactic antibody induction therapy in simultaneous pancreas and kidney transplantation.
Ringers J; van der Torren CR; van de Linde P; van der Boog PJ; Mallat MJ; Bonifacio E; Roep BO; de Fijter JW
Transplantation; 2013 Oct; 96(8):745-52. PubMed ID: 23912172
[TBL] [Abstract][Full Text] [Related]
15. Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients.
Huurman VA; Kalpoe JS; van de Linde P; Vaessen N; Ringers J; Kroes AC; Roep BO; De Fijter JW
Diabetes Care; 2006 Apr; 29(4):842-7. PubMed ID: 16567825
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and antithymocyte globulin.
Lischke R; Simonek J; Davidová R; Schützner J; Stolz AJ; Vojácek J; Burkert J; Pafko P
Transplant Proc; 2007; 39(1):205-12. PubMed ID: 17275507
[TBL] [Abstract][Full Text] [Related]
17. Antibody induction therapy for lung transplant recipients.
Penninga L; Møller CH; Penninga EI; Iversen M; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Nov; 2013(11):CD008927. PubMed ID: 24282128
[TBL] [Abstract][Full Text] [Related]
18. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
Abou-Jaoude MM; Ghantous I; Almawi WY
Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of rATg/Daclizumab vs. rATg/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up.
Ciancio G; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Ruiz P; Vianna R; Burke GW
Transpl Immunol; 2017 Feb; 40():42-50. PubMed ID: 27888093
[TBL] [Abstract][Full Text] [Related]
20. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.
Carlsen J; Johansen M; Boesgaard S; Andersen CB; Arendrup H; Aldershvilet J; Mortensen SA
J Heart Lung Transplant; 2005 Mar; 24(3):296-302. PubMed ID: 15737756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
